Physician profile
Lawrence Shombert
NPI 1679555452
$9,385.28
in general payments reported to CMS, 2019-2025
51 companies · $1,892 in 2025
The $1,892 reported for 2025 was more than what 89% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,297 · 2020: $265 · 2021: $2,403 · 2022: $710 · 2023: $69.13 · 2024: $2,748 · 2025: $1,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,602 · Consulting Fee: $1,050 · Education: $57.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,601.97 |
| Consulting Fee | $1,050.00 |
| Education | $57.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,846.80 | 2020-2025 | Tagrisso, Imfinzi, Fasenra |
| Janssen Biotech, INC. | $534.71 | 2019-2025 | Rybrevant, Carvykti, Darzalex |
| Incyte Corporation | $405.71 | 2020-2025 | Jakafi, Jakafi, Monjuvi |
| Merck Sharp & Dohme LLC | $392.92 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Eisai INC. | $318.06 | 2021-2025 | |
| Genentech USA, INC. | $296.48 | 2019-2025 | Venclexta, Itovebi, Tecentriq |
| Varian Medical Systems, INC. | $259.49 | 2019 | |
| Gilead Sciences, INC. | $194.88 | 2024-2025 | Trodelvy |
| Amgen INC. | $169.18 | 2019-2022 | |
| Novocure INC. | $167.51 | 2021-2024 | Optune |
| Genmab U.S., INC. | $161.31 | 2024-2025 | Epkinly |
| Genzyme Corporation | $145.25 | 2019 | |
| Glaxosmithkline, LLC. | $144.53 | 2024-2025 | Jemperli, Ojjaara |
| Pfizer INC. | $138.08 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $134.97 | 2019-2024 | Eliquis |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Shombert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.